COLO 320Homo sapiens (Human)Cancer cell line

Also known as: Colorado 320, COLO 320F, Co320, CoLo320, Colo320, COLO320, COLO #320, Colo 320, Colo-320, COLO-320

🤖 AI SummaryBased on 15 publications

Quick Overview

Human colorectal cancer cell line with KRAS mutations and genomic instability.

Detailed Summary

COLO 320 is a human colorectal cancer cell line derived from a primary tumor. It exhibits KRAS mutations, which are common in colorectal cancers and are associated with resistance to EGFR-targeted therapies. The cell line shows genomic instability, including microsatellite instability (MSI) and chromosomal abnormalities. COLO 320 is used in research to study the molecular mechanisms of colorectal cancer, particularly focusing on the role of KRAS mutations and genomic alterations in tumor progression. It is also utilized for drug screening and understanding the genetic basis of cancer resistance and metastasis.

Research Applications

Molecular mechanisms of colorectal cancerKRAS mutation analysisGenomic instability studiesDrug screening for EGFR resistanceTumor progression and metastasis

Key Characteristics

KRAS mutationsMicrosatellite instability (MSI)Genomic instabilityEpithelial origin
Generated on 6/17/2025

Basic Information

Database IDCVCL_1989
SpeciesHomo sapiens (Human)
Tissue SourceColon, sigmoid[UBERON:UBERON_0001159]

Donor Information

Age55
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseColon adenocarcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeDSMZ
Source IDACH-000202_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg248Trp (c.742C>T)HomozygousSomatic mutation acquired during proliferationfrom parent cell line VCaP

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
11
D16S539
11,12
D18S51
15
D19S433
16.2
D21S11
33.2
D2S1338
18,25
D3S1358
17
D5S818
12
D7S820
9,12
D8S1179
13
FGA
20
Penta D
9,12
Penta E
11
TH01
9
TPOX
8,9
vWA
15,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Mol. Cancer 16:116.1-116.16(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

Mol. Cell. Proteomics 15:124-140(2016).

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Clin. Cancer Res. 21:3695-3704(2015).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Epigenetic and genetic features of 24 colon cancer cell lines.";

Hektoen M., Lind G.E., Lothe R.A.

Oncogenesis 2:e71.1-e71.8(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Cancer Res. 70:5901-5911(2010).

Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

Garcia-Foncillas J.

Mol. Cancer 5:29.1-29.10(2006).

Assembly of microarrays for genome-wide measurement of DNA copy number.

Pinkel D., Albertson D.G.

Nat. Genet. 29:263-264(2001).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Hamelin R.

Oncogene 20:5025-5032(2001).

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).

Beta-catenin mutations in cell lines established from human colorectal cancers.

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997).

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

Cell. Immunol. 175:101-110(1997).

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Hamelin R.

Cancer Res. 57:300-303(1997).

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Thomas G., Hamelin R.

Oncogene 13:2727-2730(1996).

Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.

Moseley J.M., Martin T.J.

Cancer Res. 42:1116-1119(1982).

Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.

Scarlett J.D., Thurlow P.J., Connellan J.M., Louis C.J.

Thromb. Res. 46:715-726(1987).

Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.

Quinn L.A., Moore G.E., Morgan R.T., Woods L.K.

Cancer Res. 39:4914-4924(1979).

Web Resources